Skip to main content

Main menu

  • HOME
  • ARTICLES
    • Current Issue
    • Ahead of Print
    • Archives
    • Abstracts In Press
    • Special Issue Archive
    • Subject Collections
  • INFO FOR
    • Authors
    • Reviewers
    • Call For Papers
    • Subscribers
    • Advertisers
  • SUBMIT
    • Manuscript
    • Peer Review
  • ABOUT
    • The JABFM
    • The Editing Fellowship
    • Editorial Board
    • Indexing
    • Editors' Blog
  • CLASSIFIEDS
  • Other Publications
    • abfm

User menu

Search

  • Advanced search
American Board of Family Medicine
  • Other Publications
    • abfm
American Board of Family Medicine

American Board of Family Medicine

Advanced Search

  • HOME
  • ARTICLES
    • Current Issue
    • Ahead of Print
    • Archives
    • Abstracts In Press
    • Special Issue Archive
    • Subject Collections
  • INFO FOR
    • Authors
    • Reviewers
    • Call For Papers
    • Subscribers
    • Advertisers
  • SUBMIT
    • Manuscript
    • Peer Review
  • ABOUT
    • The JABFM
    • The Editing Fellowship
    • Editorial Board
    • Indexing
    • Editors' Blog
  • CLASSIFIEDS
  • JABFM on Bluesky
  • JABFM On Facebook
  • JABFM On Twitter
  • JABFM On YouTube
Research ArticleOriginal Research

Statin Use in the U.S. for Secondary Prevention of Cardiovascular Disease Remains Suboptimal

Quyen Ngo-Metzger, Samuel Zuvekas, Paul Shafer, Howard Tracer, Amanda E. Borsky and Arlene S. Bierman
The Journal of the American Board of Family Medicine November 2019, 32 (6) 807-817; DOI: https://doi.org/10.3122/jabfm.2019.06.180313
Quyen Ngo-Metzger
From the Agency for Healthcare Research and Quality, Rockville, MD (SZ, PS, HT, AB, ASB); Department of Health Law, Policy, and Management, School of Public Health, Boston University, Boston, MA (PS); Kaiser Permanente School of Medicine (QN-M).
MD, MPH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Samuel Zuvekas
From the Agency for Healthcare Research and Quality, Rockville, MD (SZ, PS, HT, AB, ASB); Department of Health Law, Policy, and Management, School of Public Health, Boston University, Boston, MA (PS); Kaiser Permanente School of Medicine (QN-M).
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul Shafer
From the Agency for Healthcare Research and Quality, Rockville, MD (SZ, PS, HT, AB, ASB); Department of Health Law, Policy, and Management, School of Public Health, Boston University, Boston, MA (PS); Kaiser Permanente School of Medicine (QN-M).
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Howard Tracer
From the Agency for Healthcare Research and Quality, Rockville, MD (SZ, PS, HT, AB, ASB); Department of Health Law, Policy, and Management, School of Public Health, Boston University, Boston, MA (PS); Kaiser Permanente School of Medicine (QN-M).
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amanda E. Borsky
From the Agency for Healthcare Research and Quality, Rockville, MD (SZ, PS, HT, AB, ASB); Department of Health Law, Policy, and Management, School of Public Health, Boston University, Boston, MA (PS); Kaiser Permanente School of Medicine (QN-M).
DrPH, MPP
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Arlene S. Bierman
From the Agency for Healthcare Research and Quality, Rockville, MD (SZ, PS, HT, AB, ASB); Department of Health Law, Policy, and Management, School of Public Health, Boston University, Boston, MA (PS); Kaiser Permanente School of Medicine (QN-M).
MD, MS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • References
  • Info & Metrics
  • PDF
Loading

References

  1. 1.↵
    1. Benjamin EJ,
    2. Virani SS,
    3. Callaway CW,
    4. et al
    . Heart Disease and Stroke Statistics—2018 Update: a report from the American Heart Association. Circulation 2018;137:e67–e492.
    OpenUrlFREE Full Text
  2. 2.↵
    1. Stone NJ,
    2. Robinson JG,
    3. Lichtenstein AH,
    4. et al
    . 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014;129(25 Suppl 2):S1e–S45.
    OpenUrl
  3. 3.↵
    1. Koskinas KC,
    2. Siontis GCM,
    3. Piccolo R,
    4. et al
    . Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials. Eur Heart J 2018;39:1172–1180.
    OpenUrlPubMed
  4. 4.↵
    Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349–1357.
    OpenUrlCrossRefPubMedWeb of Science
  5. 5.↵
    Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383–1389.
    OpenUrlCrossRefPubMedWeb of Science
  6. 6.↵
    1. Rodriguez F,
    2. Maron DJ,
    3. Knowles JW,
    4. Virani SS,
    5. Lin S,
    6. Heidenreich PA
    . Association between intensity of statin therapy and mortality in patients with atherosclerotic cardiovascular disease. JAMA Cardiol 2017;2:47–54.
    OpenUrl
  7. 7.↵
    1. Navarese EP,
    2. Robinson JG,
    3. Kowalewski M,
    4. et al
    . Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: a systematic review and meta-analysis. JAMA 2018;319:1566–1579.
    OpenUrl
  8. 8.↵
    1. Booth JN 3rd.,
    2. Colantonio LD,
    3. Rosenson RS,
    4. et al
    . Healthcare utilization and statin re-initiation among medicare beneficiaries with a history of myocardial infarction. J Am Heart Assoc 2018;7(10).
  9. 9.↵
    1. Johansen ME,
    2. Green LA,
    3. Sen A,
    4. Kircher S,
    5. Richardson CR
    . Cardiovascular risk and statin use in the United States. Ann Fam Med 2014;12:215–223.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Peters SAE,
    2. Colantonio LD,
    3. Zhao H,
    4. et al
    . Sex differences in high-intensity statin use following myocardial infarction in the United States. J Am Coll Cardiol 2018;71:1729–1737.
    OpenUrlFREE Full Text
  11. 11.↵
    1. Rosenson RS,
    2. Farkouh ME,
    3. Mefford M,
    4. et al
    . Trends in use of high-intensity statin therapy after myocardial infarction, 2011 to 2014. J Am Coll Cardiol 2017;69:2696–2706.
    OpenUrlFREE Full Text
  12. 12.↵
    1. Salami JA,
    2. Warraich H,
    3. Valero-Elizondo J,
    4. et al
    . National trends in statin use and expenditures in the US adult population from 2002 to 2013: insights from the Medical Expenditure Panel Survey. JAMA Cardiol 2017;2:56–65.
    OpenUrlCrossRef
  13. 13.↵
    1. Olufade T,
    2. Zhou S,
    3. Anzalone D,
    4. et al
    . Initiation patterns of statins in the 2 years after release of the 2013 American College of Cardiology/American Heart Association (ACC/AHA) Cholesterol Management Guideline in a large US health plan. J Am Heart Assoc 2017;6(5).
  14. 14.↵
    1. Okerson T,
    2. Patel J,
    3. DiMario S,
    4. Burton T,
    5. Seare J,
    6. Harrison DJ
    . Effect of 2013 ACC/AHA Blood Cholesterol Guidelines on statin treatment patterns and low-density lipoprotein cholesterol in atherosclerotic cardiovascular disease patients. J Am Heart Assoc 2017;6(3).
  15. 15.↵
    1. Pool LR,
    2. Ning H,
    3. Lloyd-Jones DM,
    4. Allen NB
    . Trends in racial/ethnic disparities in cardiovascular health among US adults from 1999–2012. J Am Heart Assoc 2017;6(9).
  16. 16.↵
    1. Lu Y,
    2. Ezzati M,
    3. Rimm EB,
    4. Hajifathalian K,
    5. Ueda P,
    6. Danaei G
    . Sick Populations and sick subpopulations: reducing disparities in cardiovascular disease between Blacks and whites in the United States. Circulation 2016;134:472–485.
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    1. Kuzawa CW,
    2. Sweet E
    . Epigenetics and the embodiment of race: developmental origins of US racial disparities in cardiovascular health. Am J Hum Biol 2009;21:2–15.
    OpenUrlCrossRefPubMedWeb of Science
  18. 18.↵
    1. Lewey J,
    2. Shrank WH,
    3. Bowry AD,
    4. Kilabuk E,
    5. Brennan TA,
    6. Choudhry NK
    . Gender and racial disparities in adherence to statin therapy: a meta-analysis. Am Heart J 2013;165:665–678, 678.e661.
    OpenUrlCrossRefPubMedWeb of Science
  19. 19.↵
    Agency for Healthcare Research and Quality. Survey background. 2009. Available from: https://meps.ahrq.gov/mepsweb/about_meps/survey_back.jsp. Accessed June 7, 2018.
  20. 20.↵
    1. Hill SC,
    2. Zuvekas SH,
    3. Zodet MW
    . Implications of the accuracy of MEPS prescription drug data for health services research. Inquiry 2011;48:242–259.
    OpenUrlPubMed
  21. 21.↵
    1. Machlin S,
    2. Cohen J,
    3. Elixhauser A,
    4. Beauregard K,
    5. Steiner C
    . Sensitivity of household reported medical conditions in the medical expenditure panel survey. Med Care 2009;47:618–825.
    OpenUrlCrossRefPubMed
  22. 22.↵
    Stata Statistical Software: Release 14 [Computer Program]. College Station, TX. StataCorp LP; 2015.
  23. 23.↵
    1. Ngo-Metzger Q,
    2. Zuvekas SH,
    3. Bierman AS
    . Estimated impact of US Preventive Services Task Force recommendations on use and cost of statins for cardiovascular disease prevention. J Gen Intern Med 2018;33:1317–1323.
    OpenUrl
  24. 24.↵
    1. Borsky A,
    2. Zhan C,
    3. Miller T,
    4. Ngo-Metzger Q,
    5. Bierman AS,
    6. Meyers D
    . Few Americans receive all high-priority, appropriate clinical preventive services. Health Aff (Millwood) 2018;37:925–928.
    OpenUrlCrossRefPubMed
  25. 25.↵
    1. McGlynn EA,
    2. Asch SM,
    3. Adams J,
    4. et al
    . The quality of health care delivered to adults in the United States. N Engl J Med 2003;348:2635–2645.
    OpenUrlCrossRefPubMedWeb of Science
  26. 26.↵
    1. Fang J,
    2. Ayala C,
    3. Luncheon C,
    4. Ritchey M,
    5. Loustalot F
    . Use of outpatient cardiac rehabilitation among heart attack survivors—20 states and the District of Columbia, 2013 and four states, 2015. MMWR Morb Mortal Wkly Rep 2017;66:869–873.
    OpenUrl
  27. 27.↵
    1. Thomas RJ,
    2. Balady G,
    3. Banka G,
    4. et al
    . 2018 ACC/AHA Clinical Performance and Quality Measures for Cardiac Rehabilitation: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. J Am Coll Cardiol 2018;71:1814–1837.
    OpenUrlFREE Full Text
  28. 28.↵
    1. Mosca L,
    2. Linfante AH,
    3. Benjamin EJ,
    4. et al
    . National study of physician awareness and adherence to cardiovascular disease prevention guidelines. Circulation 2005;111:499–510.
    OpenUrlAbstract/FREE Full Text
  29. 29.↵
    1. Keyhani S,
    2. Scobie JV,
    3. Hebert PL,
    4. McLaughlin MA
    . Gender disparities in blood pressure control and cardiovascular care in a national sample of ambulatory care visits. Hypertension 2008;51:1149–1155.
    OpenUrlCrossRefPubMed
  30. 30.↵
    1. Mosca L,
    2. Barrett-Connor E,
    3. Wenger NK
    . Sex/gender differences in cardiovascular disease prevention: what a difference a decade makes. Circulation 2011;124:2145–2154.
    OpenUrlFREE Full Text
  31. 31.↵
    1. Baigent C,
    2. Keech A,
    3. Kearney PM,
    4. et al
    . Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267–1278.
    OpenUrlCrossRefPubMedWeb of Science
  32. 32.↵
    1. Enriquez JR,
    2. Pratap P,
    3. Zbilut JP,
    4. Calvin JE,
    5. Volgman AS
    . Women tolerate drug therapy for coronary artery disease as well as men do, but are treated less frequently with aspirin, beta-blockers, or statins. Gender Med 2008;5:53–61.
    OpenUrl
  33. 33.↵
    1. Gu A,
    2. Kamat S,
    3. Argulian E
    . Trends and disparities in statin use and low-density lipoprotein cholesterol levels among US patients with diabetes, 1999–2014. Diabetes Res Clin Pract 2018;139:1–10.
    OpenUrl
  34. 34.↵
    1. Gamboa CM,
    2. Colantonio LD,
    3. Brown TM,
    4. Carson AP,
    5. Safford MM
    . Race-Sex Differences in Statin Use and Low-Density Lipoprotein Cholesterol Control Among People With Diabetes Mellitus in the Reasons for Geographic and Racial Differences in Stroke Study. J Am Heart Assoc 2017;6(5).
  35. 35.↵
    1. Adedinsewo D,
    2. Taka N,
    3. Agasthi P,
    4. Sachdeva R,
    5. Rust G,
    6. Onwuanyi A
    . Prevalence and factors associated with statin use among a nationally representative sample of US adults: National Health and Nutrition Examination Survey, 2011–2012. Clin Cardiol 2016;39:491–496.
    OpenUrl
  36. 36.↵
    1. Qureshi WT,
    2. Kaplan RC,
    3. Swett K,
    4. et al
    . American College of Cardiology/American Heart Association (ACC/AHA) Class I Guidelines for the treatment of cholesterol to reduce atherosclerotic cardiovascular risk: implications for US Hispanics/Latinos based on findings from the Hispanic Community Health Study/Study of Latinos (HCHS/SOL). J Am Heart Assoc 2017;6(5).
  37. 37.↵
    1. Kripalani S,
    2. Goggins K,
    3. Nwosu S,
    4. et al
    . Medication nonadherence before hospitalization for acute cardiac events. J Health Commun 2015;20(Suppl 2):34–42.
    OpenUrl
  38. 38.↵
    1. Havranek EP,
    2. Mujahid MS,
    3. Barr DA,
    4. et al
    . Social determinants of risk and outcomes for cardiovascular disease: a scientific statement from the American Heart Association. Circulation 2015;132:873–898.
    OpenUrlFREE Full Text
  39. 39.↵
    1. Ndumele CD,
    2. Baer HJ,
    3. Shaykevich S,
    4. Lipsitz SR,
    5. Hicks LS
    . Cardiovascular disease and risk in primary care settings in the United States. Am J Cardiol 2012;109:521–526.
    OpenUrlPubMed
  40. 40.↵
    1. Spatz ES,
    2. Sheth SD,
    3. Gosch KL,
    4. et al
    . Usual source of care and outcomes following acute myocardial infarction. J Gen Intern Med 2014;29:862–869.
    OpenUrl
  41. 41.↵
    The Patient Protection and Affordable Care Act. In. Vol 42 U.S.C. § 180012010.
  42. 42.↵
    U.S. Department of Health and Human Services, Centers for Medicare & Medicaid Services, The Center for Consumer Information & Insurance Oversight,. Affordable Care Act Implementation FAQs—Set 18. n.d. Available from: https://www.cms.gov/CCIIO/Resources/Fact-Sheets-and-FAQs/aca_implementation_faqs18.html.
  43. 43.↵
    1. Watanabe JH,
    2. Kazerooni R,
    3. Bounthavong M
    . Association of copayment with likelihood and level of adherence in new users of statins: a retrospective cohort study. J Manag Care Pharm 2014;20:43–50.
    OpenUrlPubMed
  44. 44.↵
    1. Choudhry NK,
    2. Avorn J,
    3. Glynn RJ,
    4. et al
    . Full coverage for preventive medications after myocardial infarction. N Engl J Med 2011;365:2088–2097.
    OpenUrlCrossRefPubMedWeb of Science
  45. 45.↵
    1. Bibbins-Domingo K,
    2. Grossman DC,
    3. Curry SJ,
    4. et al
    . Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement. JAMA 2016;316:1997–2007.
    OpenUrlCrossRefPubMed
  46. 46.↵
    Brandeis University. Zero copayment for certain statin prescriptions. n.d. Available from: https://www.brandeis.edu/humanresources/benefits/pdfs/2018/OptumRx_Statin_Prescriptions.pdf. Accessed August 6, 2018.
  47. 47.↵
    1. Karaca-Mandic P,
    2. Swenson T,
    3. Abraham JM,
    4. Kane RL
    . Association of Medicare Part D medication out-of-pocket costs with utilization of statin medications. Health Serv Res 2013;48:1311–1333.
    OpenUrlCrossRefPubMedWeb of Science
  48. 48.↵
    1. Tanner RM,
    2. Safford MM,
    3. Monda KL,
    4. et al
    . Primary care physician perspectives on barriers to statin treatment. Cardiovasc Drugs Ther 2017;31:303–309.
    OpenUrl
  49. 49.↵
    1. Ju A,
    2. Hanson CS,
    3. Banks E,
    4. et al
    . Patient beliefs and attitudes to taking statins: systematic review of qualitative studies. Br J Gen Pract 2018;68:e408–e419.
    OpenUrlAbstract/FREE Full Text
  50. 50.↵
    1. Booth JN 3rd.,
    2. Colantonio LD,
    3. Chen L,
    4. et al
    . Statin discontinuation, reinitiation, and persistence patterns among medicare beneficiaries after myocardial infarction: a cohort study. Circ Cardiovasc Qual Outcomes 2017;10(10).
  51. 51.↵
    1. Izuka NJ,
    2. Alexander MAW,
    3. Balasooriya-Smeekens C,
    4. Mant J,
    5. De Simoni A
    . How do stroke survivors and their carers use practitioners' advice on secondary prevention medications? Qualitative study of an online forum. Fam Pract 2017;34:612–620.
    OpenUrl
  52. 52.↵
    1. Ofori-Asenso R,
    2. Jakhu A,
    3. Zomer E,
    4. et al
    . Adherence and persistence among statin users aged 65 years and over: a systematic review and meta-analysis. J Gerontol A Biol Sci Med Sci 2018;73:813–819.
    OpenUrl
  53. 53.↵
    1. Inselman J,
    2. Branda M,
    3. Castaneda-Guarderas A,
    4. et al
    . Uptake and documentation of the use of an encounter decision aid in usual practice: a retrospective analysis of the use of the statin/aspirin choice decision aid. Med Decis Making 2016;36:557–561.
    OpenUrlCrossRefPubMed
  54. 54.↵
    1. Zuvekas SH,
    2. Olin GL
    . Validating household reports of health care use in the medical expenditure panel survey. Health Serv Res 2009;44(5 Pt 1):1679–1700.
    OpenUrlCrossRefPubMedWeb of Science
  55. 55.↵
    1. Cheak-Zamora NC,
    2. Wyrwich KW,
    3. McBride TD
    . Reliability and validity of the SF-12v2 in the medical expenditure panel survey. Qual Life Res 2009;18:727–735.
    OpenUrlCrossRefPubMedWeb of Science
  56. 56.↵
    1. Mercado C,
    2. DeSimone AK,
    3. Odom E,
    4. Gillespie C,
    5. Ayala C,
    6. Loustalot F
    . Prevalence of cholesterol treatment eligibility and medication use among adults–United States, 2005–2012. MMWR Morb Mortal Wkly Rep 2015;64:1305–1311.
    OpenUrlCrossRefPubMed
  57. 57.↵
    1. Johansen ME,
    2. Hefner JL,
    3. Foraker RE
    . Antiplatelet and statin use in US patients with coronary artery disease categorized by race/ethnicity and gender, 2003 to 2012. Am J Cardiol 2015;115:1507–1512.
    OpenUrl
  58. 58.↵
    1. Sarpong EM,
    2. Zuvekas SH
    . Trends in statin therapy among adults (age ≥ 18), United States, 2000 to 2011. In: Statistical Brief (Medical Expenditure Panel Survey (US)). Rockville, MD: Agency for Healthcare Research and Quality (US); 2001.
  59. 59.↵
    1. Sarpong EM,
    2. Zuvekas SH
    . Changes in statin therapy among adults (age ≥ 18) by selected characteristics, United States, 2000–2001 to 2010–2011. In: Statistical Brief (Medical Expenditure Panel Survey (US)). Rockville, MD: Agency for Healthcare Research and Quality (US); 2001.
  60. 60.↵
    IMS Institute for Health Informatics. Medicines Use and Spending in the U.S., A Review of 2015 and Outlook to 2020. 2016. Available from: https://morningconsult.com/wp-content/uploads/2016/04/IMS-Institute-US-Drug-Spending-2015.pdf.
  61. 61.↵
    1. Toth PP,
    2. Patti AM,
    3. Giglio RV,
    4. et al
    . Management of statin intolerance in 2018: still more questions than answers. Am J Cardiovasc Drugs 2018;18:157–173.
    OpenUrl
  62. 62.↵
    1. Grundy SM,
    2. Stone NJ,
    3. Bailey AL,
    4. et al
    . AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. J Am Coll Cardiol 2018;2018:25709.
    OpenUrl
  63. 63.↵
    1. Hirsch AT,
    2. Criqui MH,
    3. Treat-Jacobson D,
    4. et al
    . Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 2001;286:1317–1324.
    OpenUrlCrossRefPubMedWeb of Science
  64. 64.↵
    1. Cohen JD,
    2. Aspry KE,
    3. Brown AS,
    4. et al
    . Use of health information technology (HIT) to improve statin adherence and low-density lipoprotein cholesterol goal attainment in high-risk patients: proceedings from a workshop. J Clin Lipidol 2013;7:573–609.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

The Journal of the American Board of Family     Medicine: 32 (6)
The Journal of the American Board of Family Medicine
Vol. 32, Issue 6
November-December 2019
  • Table of Contents
  • Table of Contents (PDF)
  • Cover (PDF)
  • Index by author
  • Back Matter (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on American Board of Family Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Statin Use in the U.S. for Secondary Prevention of Cardiovascular Disease Remains Suboptimal
(Your Name) has sent you a message from American Board of Family Medicine
(Your Name) thought you would like to see the American Board of Family Medicine web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
4 + 16 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Statin Use in the U.S. for Secondary Prevention of Cardiovascular Disease Remains Suboptimal
Quyen Ngo-Metzger, Samuel Zuvekas, Paul Shafer, Howard Tracer, Amanda E. Borsky, Arlene S. Bierman
The Journal of the American Board of Family Medicine Nov 2019, 32 (6) 807-817; DOI: 10.3122/jabfm.2019.06.180313

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Statin Use in the U.S. for Secondary Prevention of Cardiovascular Disease Remains Suboptimal
Quyen Ngo-Metzger, Samuel Zuvekas, Paul Shafer, Howard Tracer, Amanda E. Borsky, Arlene S. Bierman
The Journal of the American Board of Family Medicine Nov 2019, 32 (6) 807-817; DOI: 10.3122/jabfm.2019.06.180313
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Methods
    • Results
    • Discussion
    • Conclusions
    • Acknowledgments
    • Appendix
    • Notes
    • References
  • Figures & Data
  • References
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Discharge prescription patterns for antiplatelet and statin therapy following carotid endarterectomy: an analysis of the vascular quality initiative
  • Effects of statin therapy on coronary plaque volume by decreasing CRP/hsCRP levels: A meta-regression of randomized controlled trials
  • New Research on Back Pain, Diet and Diabetes, Advanced Care Planning, and Other Issues Frequently Seen in Family Medicine
  • Google Scholar

More in this TOC Section

  • Identifying and Addressing Social Determinants of Health with an Electronic Health Record
  • Integrating Adverse Childhood Experiences and Social Risks Screening in Adult Primary Care
  • A Pilot Comparison of Clinical Data Collection Methods Using Paper, Electronic Health Record Prompt, and a Smartphone Application
Show more Original Research

Similar Articles

Keywords

  • Atherosclerosis
  • Cardiovascular Diseases
  • Chronic Disease
  • Hypercholesterolemia
  • Hyperlipidemia
  • Logistic Models
  • Preventive Medicine
  • Secondary Prevention
  • Statins
  • Surveys and Questionnaires

Navigate

  • Home
  • Current Issue
  • Past Issues

Authors & Reviewers

  • Info For Authors
  • Info For Reviewers
  • Submit A Manuscript/Review

Other Services

  • Get Email Alerts
  • Classifieds
  • Reprints and Permissions

Other Resources

  • Forms
  • Contact Us
  • ABFM News

© 2025 American Board of Family Medicine

Powered by HighWire